Importance of the time of initiation of mineralocorticoid receptor antagonists on risk of mortality in patients with heart failure

Introduction: Several studies have definitively shown the benefit of mineralocorticoid receptor antagonists (MRAs) in patients with heart failure (HF). However, very few prior studies examined the relationship between the timing of initiation of MRAs and prognosis. In addition, on this topic, there...

Full description

Bibliographic Details
Main Authors: Rosario Rossi, Nicola Crupi, Francesca Coppi, Daniel Monopoli, Fabio Sgura
Format: Article
Language:English
Published: SAGE Publications 2015-03-01
Series:Journal of the Renin-Angiotensin-Aldosterone System
Online Access:https://doi.org/10.1177/1470320313482603
_version_ 1797283524484530176
author Rosario Rossi
Nicola Crupi
Francesca Coppi
Daniel Monopoli
Fabio Sgura
author_facet Rosario Rossi
Nicola Crupi
Francesca Coppi
Daniel Monopoli
Fabio Sgura
author_sort Rosario Rossi
collection DOAJ
description Introduction: Several studies have definitively shown the benefit of mineralocorticoid receptor antagonists (MRAs) in patients with heart failure (HF). However, very few prior studies examined the relationship between the timing of initiation of MRAs and prognosis. In addition, on this topic, there is no information regarding the specific population of patients suffering a first episode of decompensated congestive HF. Methods: We studied a homogenous cohort of patients discharged alive from our hospital after a first episode of decompensated congestive HF, in order to clarify the association between time of aldosterone receptor antagonist (ARA) initiation (within the first 90 days after hospital discharge) and mortality. Our population was composed of a series of consecutive patients. All-cause mortality was compared between patients who initiated MRAs at discharge (early group) and those who initiated MRAs one month later and up to 90 days after discharge (delayed group). We used prescription time distribution matching to control for survival difference between groups. Results: The early and delayed groups consisted of 365 and 320 patients, respectively. During the one-year follow-up, a significant difference in mortality was demonstrated between groups. Adjusted hazard ratios (HRs) for early versus delayed initiation were 1.72 (95% confidence interval (CI) 0.96 to 2.84) at six months, and 1.93 (95% CI 1.18 to 3.14) at one year. Conclusions: Delay of MRA initiation up to 30 to 90 days after discharge implies a significant increase in mortality compared with MRA initiation at discharge, after a first episode of decompensate congestive HF.
first_indexed 2024-03-07T17:32:58Z
format Article
id doaj.art-4a82c4908691461ba9c5da860a095dcc
institution Directory Open Access Journal
issn 1470-3203
1752-8976
language English
last_indexed 2024-03-07T17:32:58Z
publishDate 2015-03-01
publisher SAGE Publications
record_format Article
series Journal of the Renin-Angiotensin-Aldosterone System
spelling doaj.art-4a82c4908691461ba9c5da860a095dcc2024-03-02T17:28:25ZengSAGE PublicationsJournal of the Renin-Angiotensin-Aldosterone System1470-32031752-89762015-03-011610.1177/1470320313482603Importance of the time of initiation of mineralocorticoid receptor antagonists on risk of mortality in patients with heart failureRosario RossiNicola CrupiFrancesca CoppiDaniel MonopoliFabio SguraIntroduction: Several studies have definitively shown the benefit of mineralocorticoid receptor antagonists (MRAs) in patients with heart failure (HF). However, very few prior studies examined the relationship between the timing of initiation of MRAs and prognosis. In addition, on this topic, there is no information regarding the specific population of patients suffering a first episode of decompensated congestive HF. Methods: We studied a homogenous cohort of patients discharged alive from our hospital after a first episode of decompensated congestive HF, in order to clarify the association between time of aldosterone receptor antagonist (ARA) initiation (within the first 90 days after hospital discharge) and mortality. Our population was composed of a series of consecutive patients. All-cause mortality was compared between patients who initiated MRAs at discharge (early group) and those who initiated MRAs one month later and up to 90 days after discharge (delayed group). We used prescription time distribution matching to control for survival difference between groups. Results: The early and delayed groups consisted of 365 and 320 patients, respectively. During the one-year follow-up, a significant difference in mortality was demonstrated between groups. Adjusted hazard ratios (HRs) for early versus delayed initiation were 1.72 (95% confidence interval (CI) 0.96 to 2.84) at six months, and 1.93 (95% CI 1.18 to 3.14) at one year. Conclusions: Delay of MRA initiation up to 30 to 90 days after discharge implies a significant increase in mortality compared with MRA initiation at discharge, after a first episode of decompensate congestive HF.https://doi.org/10.1177/1470320313482603
spellingShingle Rosario Rossi
Nicola Crupi
Francesca Coppi
Daniel Monopoli
Fabio Sgura
Importance of the time of initiation of mineralocorticoid receptor antagonists on risk of mortality in patients with heart failure
Journal of the Renin-Angiotensin-Aldosterone System
title Importance of the time of initiation of mineralocorticoid receptor antagonists on risk of mortality in patients with heart failure
title_full Importance of the time of initiation of mineralocorticoid receptor antagonists on risk of mortality in patients with heart failure
title_fullStr Importance of the time of initiation of mineralocorticoid receptor antagonists on risk of mortality in patients with heart failure
title_full_unstemmed Importance of the time of initiation of mineralocorticoid receptor antagonists on risk of mortality in patients with heart failure
title_short Importance of the time of initiation of mineralocorticoid receptor antagonists on risk of mortality in patients with heart failure
title_sort importance of the time of initiation of mineralocorticoid receptor antagonists on risk of mortality in patients with heart failure
url https://doi.org/10.1177/1470320313482603
work_keys_str_mv AT rosariorossi importanceofthetimeofinitiationofmineralocorticoidreceptorantagonistsonriskofmortalityinpatientswithheartfailure
AT nicolacrupi importanceofthetimeofinitiationofmineralocorticoidreceptorantagonistsonriskofmortalityinpatientswithheartfailure
AT francescacoppi importanceofthetimeofinitiationofmineralocorticoidreceptorantagonistsonriskofmortalityinpatientswithheartfailure
AT danielmonopoli importanceofthetimeofinitiationofmineralocorticoidreceptorantagonistsonriskofmortalityinpatientswithheartfailure
AT fabiosgura importanceofthetimeofinitiationofmineralocorticoidreceptorantagonistsonriskofmortalityinpatientswithheartfailure